O utcome measurement is a cornerstone of quality improvement. Continuous outcome monitoring provides an approach to guide improvements in quality of care by providing feedback about the overall effects of changes in practice. Monitoring can be used to detect a change in outcomes so the process of care can be examined, reinforcing beneficial practices and eliminating factors that degrade performance. Alternatively, monitoring can be used to prospectively evaluate single or multiple interventions. In a culture of change, driven by innovation and the incorporation of empirical research-based evidence (evidence-based medicine), continuous monitoring of outcomes has the potential to direct the evolution of practice toward higher quality.
In medical applications, as in industry, process performance may be better understood with evaluation of the consequences of process interventions and provision of sequential information (1) . Some quality surveillance applications have been described in the medical literature, including monitoring clinical outcomes in colonoscopy (2) (3) (4) , pediatric cardiac surgery (5) , and adult thoracic surgery (6) . Continuous surveillance accumulates evidence to detect subtle changes, may detect cyclic changes, and can offer contemporaneous feedback and analysis.
Process monitoring may include Shewhart p charts and the cumulative sum (CUSUM) procedure. The p chart can detect large changes in a rate of occurrence, and the CUSUM is suited to detecting small persistent changes in an event rate over time (7) .
Manufacturing and industrial applications typically have homogeneous input specifications, so traditional control chart approaches make no adjustment for different risks of failure. In contrast, patients referred to intensive care units (ICU) are heterogeneous in their clinical presentation and physiology. Case-mix is a term that broadly describes the considerable variability in patients' condition and severity. Incorporation of a validated risk of death adjustment to control chart analysis is conceptually similar to modeling the effects of confounding variables in a controlled study. In risk-adjusted (RA) outcome monitoring, the confounding factor is mortality risk.
In the RA p chart, the observed mortality rate is compared with control limits estimated around the predicted mortality rate accounting for case-mix, patient numbers, and random variation (Appendix 1). As with outcome analysis with the standardized mortality ratio, repeated sample periods will increase the probability of false alarm in a predictable manner.
Steiner et al. (8, 9 ) developed a RA CUSUM procedure for continuous monitoring based on the likelihood ratio. They propose an efficient graphical method for identifying when there is either a substantial decrease or increase in RA mortality (Appendixes 2 and 3).
In this report, an RA p chart and a two-sided RA CUSUM chart are applied to data from an ICU data set to monitor ICU outcomes. The RA is based on the locally validated Acute Physiology and Chronic Health Evaluation (APACHE) III (10) model. This is the first report of outcome surveillance procedures proposed to continuously monitor local changes in RA mortality performance in ICU.
MATERIALS AND METHODS
The data set is drawn from 3398 consecutive ICU admissions (3159 hospital admissions from January 1, 1995, to January 1, 1998) to the Princess Alexandra Hospital in Brisbane, Australia. The Princess Alexandra Hospital ICU provides medical and surgical critical care services to an 858-bed adult metropolitan teaching hospital, which is the regional center for trauma, major surgery, medical subspecialties, and psychiatry.
The ICU mortality analysis included all eligible admissions to the ICU, including readmissions. The hospital mortality analysis excluded all ICU readmissions during an episode of hospitalization to prevent double counting of outcomes. For each admission, estimates of in-ICU and in-hospital mortality rates were calculated with the APACHE III equation (10) . The details of local performance and model validation have been described (11) . The receiver operating characteristic curve area was 0.90, and calibration curves and goodness-of-fit analysis indicated that the models with proprietary adjustments for hospital characteristics were well calibrated at this site during the period of analysis. Proprietary adjustments to the standard APACHE III model included the additional variable of pre-ICU treatment period and information about the institution size, teaching status, and region. In the case of the Princess Alexandra Hospital, a similar hospital model references the predictions to teaching hospitals of similar size in the Midwest region of the United States (C Alzola, personal communication, 1999).
Two control chart approaches to analysis of RA ICU and hospital mortality data are presented. Shewhart p charts (Figs. 1 and 2) were plotted by using semiannual observed mortality rates compared with APACHE III predicted mortality rates with control limits set at Ϯ1.96 SD of the predicted mortality. Control limits are dependent on admission numbers and case-mix and are calculated from the APACHE III predicted mortality and an estimate of the SD of the predicted mortality rate. Appendix 1 provides references and the formulas for these estimates. In the design of the chart, limits were chosen for which, in a single observation period, the power to detect a doubling or halving of the odds of death would be estimated as Ն0. 8 .
The second chart analysis is a likelihoodbased CUSUM chart to follow RA mortality. In Appendix 2, the CUSUM approach for continuous monitoring is described in detail. Appendix 3 presents an analysis of the performance and a description of the surveillance method in terms of run length characteristics.
The performance characteristics of the RA p chart and the RA CUSUM can be analyzed either in terms of the probability of signal during a period of analysis or the distributional features of the number of observations before a signal occurs, under both unchanged and changed odds ratios (OR). The first approach, the probability of false alarm and power of the technique, is familiar. Appendix 1 presents the formulas for this analysis of the RA p chart. Appendix 3 describes the analysis of the run length characteristics of the RA CUSUM. When the RA performance has not changed, the false-alarm run length is somewhat analogous to a measure of specificity. Where the RA performance has changed, run length to signal can be thought of as similar to sensitivity.
RESULTS
The RA Shewhart p charts plotting semiannual mortality rates for in-ICU mortality ( Fig. 1 ) and in-hospital mortality (Fig. 2) are plotted for the 3-yr period 1995-1997.
In Figure 1 , the observed in-ICU mortality was close to predicted, except for the first half of 1997, during which the observed mortality rate decreased below the lower control limit of the predicted mortality. In Figure 2 , the observed inhospital mortality was higher than expected, with each of the first three review period rates falling beyond the upper 1.96 SD control limit.
The data are presented by using twosided RA CUSUM charts for the ICU (Fig.  3 ) and the hospital outcomes (Fig. 4) . In each, the upper CUSUM was designed to detect a doubling of the odds of death (OR A ϭ 2), and the lower chart was designed to detect a halving of the odds of death (OR A ϭ 0.5). When the CUSUM crosses the control limit (h ϩ or h Ϫ ), enough evidence of a change in the ICU mortality rate has accumulated, and the CUSUM "signals." At this point, the CU-SUM is reset to zero, and monitoring is resumed. Figure 3 shows the variation around the baseline, with no accumulation of evidence that the odds of an ICU death are either substantially higher or lower than expected with the APACHE III ICU mortality model, in the first 2,600 patients. However, by admission number 2695, the CUSUM decreased below h Ϫ . Either this signal was a random statistical event or the odds of in-ICU death were below predicted. The CUSUM was reset to zero, and there were no further signals. Figure 4 presents a different pattern. The hospital RA CUSUM signaled an increased mortality by patient 533, when the upper control limit h ϩ was exceeded. The upper RA CUSUM was reset to zero, and the upper control limit was exceeded again at patient 1119. It is reasonable to conclude that this represents increased odds of RA hospital mortality during this period. However, in a prospective application, a signal would prompt action, and subsequent signals would be interpreted in the context of any actions taken.
DISCUSSION AND CONCLUSIONS
RA control charting allows continuous monitoring of ICU outcomes while accounting for dynamic case-mix. Two different approaches are compared: the RA p chart is a summary charting technique, and the RA CUSUM is a sequential charting technique. This case series presents charts with signals of increased RA mortality exceeding APACHE III predictions and a signal representing random variation, or mortality decreasing below predicted.
The RA p chart analyses compare an observed mortality rate with the predicted mortality rate. In this example, by using Ϯ1.96 SD control limits and semiannual reviews, the design of the RA p chart corresponds for a single observation period to the detection of a doubling of the odds of death (OR ϭ 2) with a power of 0.98 -0.99 for in-ICU mortality and 0.93-0.98 for in-hospital mortality. For a smaller increase in odds of death, say, OR ϭ 1.5, the corresponding power estimates are in the ranges of 0.65-0.76 for in-ICU mortality and 0.45-0.59 for in-hospital mortality. The RA p chart will demonstrate large differences in RA performance but may be insensitive to small differences in RA mortality.
However, with six observation periods, the probability of one or more false alarms, where the probability of death is accurately predicted by the RA tool and where control limits are set at Ϯ1.96 SD, is 1 Ϫ 0.95 6 ϭ 0.26. A false alarm would occur, on average, approximately every 10 yrs. It is very likely that the three signals of increased in-hospital mortality during the initial three semiannual reviews represent true increased odds of death relative to the APACHE III predictions. The signals of mortality below predicted in both the in-ICU and in-hospital mortality charts may be either chance events or real differences.
The RA p chart can be designed prospectively to meet meaningful performance specifications. For example, to detect a doubling of odds of in-ICU death with ␣ ϭ 0.05 and 1 Ϫ ␤ ϭ 0.9, given the case-mix of the sample, approximately 300 cases would be required ‫41ف(‬ wks).
With the design of the RA CUSUM, the average run length to signal, where there are no changes in the odds of in-ICU death, is 7150 admissions; that of inhospital death is 5400 admissions. This is, on average, a false signal of increased RA mortality every 6.3 and 5.1 yrs, respectively. We conclude, again, that the signals of observed in-hospital mortality exceeding predicted are probably truepositive signals. The significance of the signals of mortality less than predicted is unclear.
The choice of a specific control limit is a management decision, and chart design balances the risks of false signals and of not detecting a change in RA performance. Figure 5 in Appendix 3 shows the relationship between average run length and the changed OR in the context of in-ICU mortality and the specific control limit, h ϭ 4.5. For example, the average run length to signal of the RA CUSUM when the OR is 2 is 125 cases ‫5ف(‬ wks).
The RA CUSUM may detect real changes sooner than the RA p chart, simply because the p chart cannot signal before the end of each observation period. The RA p chart requires arbitrary, defined periods of analysis and so may miss or delay a signal if changes occur halfway through a monitoring period. A characteristic of monitoring outcomes for quality management, compared with controlled interventional studies, is that the timing of changes may not be controlled or predicted in advance, or multiple, staged changes may occur. In contrast, the RA CUSUM can signal irrespective of the timing of the change in odds of death relative to the monitoring period if the increased OR is sustained. After signaling, the chart will resume accumulating evidence.
To interpret the significance of signals on RA control charts, we must consider the possibilities of random variation, systematic problems with model fit, and clinically relevant changes in the quality (12) (13) (14) but do not specify how much random variation in the plot is expected. Sherlaw-Johnson et al. (15) provide nested prediction intervals that have been applied to tracking cumulative mortality from myocardial infarction (16) . However, the accumulating probability of false alarm with repeated analysis makes continuous monitoring of outcomes difficult to interpret.
In the analysis presented, either random variation or a nonsustained reduction in the odds of death would account for a lower than predicted mortality in the later part of the in-ICU and inhospital series. However, the longer period of an apparent higher than predicted hospital mortality, with repeat signals, is less likely to be due to chance.
These techniques are as much a form of continuous assessment of RA tool calibration as of the clinical process of care. Where a change is signaled, either the model fit or the clinical milieu may have changed. It is mathematically not possible to separate the two possibilities, and, clearly, the model fit is dependent, among other things, on the clinical process. Changes in data collection (17, 18) , patient case-mix (19) , admission lead time (20) , discharge practices (21), observed mortality rate (22) , rule interpretations, and transcription ambiguities (23) all can potentially interfere with ICU mortality prediction systems, including the APACHE III system. It is essential that the models for RA be validated on site and that model or data failure always be considered as a possible cause for a signal. This application uses a validated generalization of an existing model (11), but the "black box" nature of the APACHE III system makes it difficult to analyze the role of the RA model when a signal is detected. Recalibration of an existing ICU outcome model (21, 24, 25) or application of locally developed models would be equally appropriate and more transparent.
In this analysis, the data collection and application of the RA tool were not altered, and a change in survival is possible. An improvement in senior staffing was a discrete milestone that occurred around admission number 1100. An ongoing multidisciplinary, evidence-based review of all aspects of patient care followed and continues, similar to guidelines recently proposed independently elsewhere (26) . No further signals of increased RA mortality were seen in this analysis.
Considering these caveats, RA outcome monitoring is proposed as a method of quality management. General ICUs seldom have the caseload and never have the resources to offer controlled prospective evaluation of incremental change. Cardiac surgery is a common group of procedures, yet a power analysis of 43 Veterans Affairs hospitals in the United States (1987-1992) (27) found that only one institution had enough cases to potentially detect a doubling of surgical mortality in a 6-mo period (␣ ϭ 0.05; 1 Ϫ ␤ ϭ 0.8). A typical, general ICU has a myriad of diagnoses. APACHE III has 95 disease groups and more than 250 diagnoses. Well-designed controlled studies can demonstrate the effectiveness of a clinical intervention under test conditions, but application to local clinical practice conditions may be a concern (6). Collecting similar patients leads to delays in data accumulation, with therapeutic creep and continual change rendering historical findings obsolete. Excess mortality during case collection may be an unacceptable price to pay for specificity. Timely recognition may support further improvements or prevent unnecessary increased mortality.
Continuous monitoring of RA outcomes allows a broad evaluation of a clinical milieu. These are not tools to assess a change that affects only a small number Figure 5 . Average run length of cumulative sum for changes in the odds ratio of risk-adjusted mortality. The distribution of average run length is based on the case mix of the Princess Alexandra Hospital intensive care unit and the choice of h at Ϯ4.5. An odds ratio of 1 gives an average run length of 7400, whereas a doubling or halving of the odds ratio should signal by 125 patients on average. of patients; they are more suited to monitoring changes that affect all patients or the entire clinical process. RA monitoring is not a substitute for rigorous controlled evaluation, but, then, controlled studies are not necessarily practical for the evaluation of a culture of innovation, evolution, and incremental change.
This article presents the first continuous monitoring technique of outcomes in ICU with RA control charting to track local RA mortality performance. Medical practice is an evolutionary process, which, we assume, moves toward improved patient outcomes. The methods are proposed so that we may contemporaneously learn the most from our patient data, rather than be judged by others in retrospect. 
APPENDIX 1
Control Limits and Power Analysis of Shewhart p Chart. The modified p chart plots observed mortality rates, predicted mortality rates, and estimated control limits. In situations in which the cases have a differing expectation of mortality, the usual formulas for calculation of control limits (28, 29) are modified.
Control limits are dependent on admission numbers and case mix and are calculated from the Acute Physiology and Chronic Health Evaluation (APACHE) III mortality predictions. An estimate is made of the SD of the predicted mortality rate (15, 30) . This leads to
where: CL are the control limits, n is the number of cases in each block of admissions, indexed by i, p i is the predicted risk of death, K is the number of standard deviations chosen for control limits, and Ϯ1.96 SD is equivalent to an alpha error of .05 for a single observation. More accurate characterization of the distribution of the observed mortality for the Princess Alexandra Hospital data set, using simulations or a Markov, iterative approach demonstrates that this estimate of the control limits is good to Ϯ2 SD, but it becomes less reliable for decision thresholds beyond. In monitoring health outcomes, particularly mortality, control limits beyond of Ϯ2 SD may demand an inappropriately high specificity before prompting review and action. Also, given the performance of the RA models, accuracy beyond 2 SD may be unrealistic.
The power of the analysis to detect changes in the RA mortality in any single observation period can be estimated given case mix, block grouping size, and an alternative hypothesis to define risk of death. This calculation may be useful in the design of the chart.
Where ⌽(x) is the cumulative normal distribution for the value x and Q i is the alternative risk of death. In this series, it is based on an altered odds ratio (OR A ). If
APPENDIX 2
Risk-adjusted Cumulative Sum Procedure. The development of the risk-adjusted cumulative sum (RA CU-SUM) approach has been described in detail elsewhere (8, 9, 31 Because each patient's mortality risk may vary, OR A is specified as an OR. In this example, we design a chart to detect a doubling in the odds of failure, so we set OR A ϭ 2. An increase in the OR to 2 is equivalent to an increase in the overall ICU mortality rate from the current 9.9% (16% in hospital) to 18% (27.6% in hospital).
The score, (w t ) for each patient is derived using a log likelihood ratio. It is given by the logarithm of the ratio of the probability of the outcome observed, under the alternative hypothesis of interest, which is defined through OR A and p t , to the probability under the currently estimated risk, defined as p t if the outcome of interest is death and (1Ϫ p t ) if the outcome is survival.
The CUSUM can be regarded as a formal sequential procedure for testing the null hypothesis: H 0 : OR ϭ 1, vs. the alternative hypothesis, H A : OR ϭ OR A .
When designing a chart to detect increases in the ICU mortality rate (i.e., ORA Ͼ 1), the w t associated with mortality are positive, whereas successes receive a negative score. For example, if OR A ϭ 2, then a patient who has a predicted ICU mortality risk of 1% would contribute a score equal to 0.68 if her or she dies and Ϫ0.01 if he or she lives. A patient who has a predicted mortality risk of 30% would contribute a score equal to 0.43 if he or she dies and Ϫ0.26 if he or she lives. The "penalty" for a death of a low-risk patient is more severe than for a death of a higher-risk patient.
To complete the CUSUM design, we must choose a value for the control limit (h). For each of the CUSUMs, the choice of h involves an inherent tradeoff based on the in-control and out-ofcontrol average run length of the proposed procedure (Appendix 3). For the CUSUM designed to detect increases (decreases) in the ICU mortality rate, setting the control limit h at 4.5 (Ϫ4.5) gives an average run length of around 7,150 patients when the OR is unchanged.
For presentation on the same diagram of two CUSUM procedures on the same data series, we have used the convention that if OR A Ͻ 1, X t ϭ min͑0, X tϪ1 Ϫ w t ͒ [7] and the CUSUM accumulates a negative value. The procedure signals when X t falls below h -ϭ Ϫ4.5
APPENDIX 3
Analysis of Performance of the RA CU-SUM Monitoring Scheme. A CUSUM is designed to continually monitor the ICU performance until a signal occurs. The procedure will, theoretically, always eventually signal because the testing (monitoring) is continued indefinitely. The number of patients until the CUSUM first exceeds the control limit is called the run length of a CUSUM. If the ICU mortality rate has not changed, a signal will represent a false alarm, and long run lengths are desirable. If the mortality has increased substantially, short run lengths are desirable.
The run length is a random variable whose distribution represents all the possible runs that may arise given a particular overall mortality rate, patient mix, and the effects of chance. Thus, the average run length of the CUSUM when the mortality rate has not changed is somewhat similar to the type I error rate of a traditional statistical test. Likewise, the average run length of the CUSUM when the mortality rate has increased substantially is somewhat analogous to the power of a traditional statistical test. Determining the average run length of a CUSUM at the design stage is computational intensive because it is based on all possible outcomes for a long series of patients, but it may be closely approximated (31). Selection of h represents a trade-off between false alarms and delay in detection of a true change in the odds of death.
To quantify the ability of the CUSUM procedure to quickly detect increases in the odds of death, Figure 5 shows a plot of the average run length against a measure of the in-ICU performance given in terms of the RA odds of mortality. We use the patient mix, in terms of APACHE III risk of death estimates in the current data set, to estimate these distributions. We see in Figure 5 that substantial changes in the OR result in a rapid decrease in the expected run length of the CUSUM.
